Journal Article Summary
The article investigates the role of the 5-hydroxytryptamine receptor 2A (5HT2AR) in diabetic peripheral neuropathy (DPN), a common complication of diabetes that can lead to severe nerve damage and increased risk of foot ulcers. Understanding the mechanisms behind DPN is crucial, as current treatments mainly focus on alleviating symptoms rather than addressing the underlying causes. The study highlights the pathological elevation of 5HT2AR in nerve tissues of DPN patients and model mice, suggesting that targeting this receptor could offer a new therapeutic approach to mitigate the effects of DPN.
The researchers conducted experiments using clinical samples from late-stage DPN patients and diabetic mice models. They found that desloratadine (DLT), a selective antagonist of 5HT2AR, effectively reduced the formation of neutrophil extracellular traps (NETs), which are linked to vascular dysfunction and neuroinflammation in DPN. The study demonstrated that DLT treatment improved neurological function and reduced nerve damage in the mice, indicating its potential as a therapeutic agent for DPN by inhibiting the detrimental effects of NETs.
However, the study has limitations, including reliance on animal models, which may not fully replicate human conditions. Additionally, the long-term effects of DLT and its potential side effects need further investigation. Patients and caregivers should discuss these findings with healthcare professionals, particularly regarding the management of DPN and the potential for new treatment options targeting 5HT2AR. Understanding the implications of this research could lead to more effective strategies for preventing and treating DPN in diabetic patients.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Lu Dayun, Ruan Yuan, Zhou Fan, Ma Yan, Chang Jieru, Wei Yuxi, Xu Rui, Wang Jiaying, et al.. Desloratadine as the selective 5HT2AR antagonist suppresses neutrophil extracellular traps formation to ameliorate diabetic peripheral neuropathy pathology. Journal of Neuroinflammation 2025. DOI: 10.1186/s12974-025-03581-6. PMID: 41194218. PMCID: PMC12587694.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby --- Over The Counter
Loratadine 10 mg — 300 Count Bottle — Generic For Claritin — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
